A US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for TNBC. Key pipeline assets highlighted include Enhertu, datopotamab deruxtecan, and Cosela. 

This interview was conducted on 19 July 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357. 

For our disclosures, please read the Biomedtracker Research Standards.